Related Experiment Video

Updated: May 12, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myeloma

Amrita Y Krishnan1, Shirong Wang, Joycelynne M Palmer

  • 1Department of Hematology & Hematopoietic Cell Transplantation.

Leukemia & Lymphoma
|April 12, 2013
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
08:17

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Experiment Videos

Last Updated: May 12, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
08:17

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Articles linked to this work by shared authors, journal, and citation graph.

CAR T‑Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B‑Cell ALL.

Transplantation and cellular therapy·2026

Structure-function modification of soluble dietary fiber polysaccharides from lignified bamboo shoots through microwave-assisted enzymatic disruption of lignocellulosic barrier.

Carbohydrate polymers·2026

Combining Radiation Therapy and Tumor-Infiltrating Lymphocyte Therapy: Biological Rationale, Clinical Synergies, and Future Directions.

Current oncology (Toronto, Ont.)·2026

m6A mRNA methylation regulates pancreatic α-cell plasticity.

Nature metabolism·2026

The Python simulations of chemistry framework: 10 years of an open-source quantum chemistry project.

The Journal of chemical physics·2026

Gut Microbiome Composition Is Associated With Response to CD38 Antibody (Daratumumab) Treatment Among Relapsed Multiple Myeloma Patients.

Clinical lymphoma, myeloma & leukemia·2026

Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports.

Leukemia & lymphoma·2026

Long-term mental health service utilization among patients with diffuse large B-cell lymphoma: a population-based study.

Leukemia & lymphoma·2026

Emerging drug profile: bexobrutideg.

Leukemia & lymphoma·2026

Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.

Leukemia & lymphoma·2026

Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies.

Leukemia & lymphoma·2026

Evaluating YouTube videos for Hodgkin lymphoma patient education.

Leukemia & lymphoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us